WP1 issue panel on RWE in HTA decision-making across Europe was the second most popular session at the recent International Society For Pharmacoeconomics and Outcomes Research (ISPOR) European Congress, 8th-12th November, Amsterdam.
Panellists Alexandre Joyeux (Novartis), Keith Abrams (University of Leicester), and Wim Goettsch (ZIN), as well as session chair Sarah Garner (NICE) introduced the IMI GetReal consortium and discussed how desirable, feasible, and acceptable the use of real world evidence in drug development is to inform health technology assessments across Europe. Preliminary results from WP1 Work Stream 1 were shared with the estimated 900 delegates who attended the session. Other IMI GetReal partners such as LA-SER ANALYTICA and the University of Bern also took part in promoting the consortium’s goals throughout the congress in an educational symposium and poster presentations.
Overall, ISPOR 17th Annual European Congress highlighted how timely and relevant IMI GetReal is to HTA decision making in Europe and the high level of interest in the project.